Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Revolution Medicines (United States) | Researchclopedia

Back to institutions

Revolution Medicines (United States)

Redwood Citycompany

300

Works

54,877

Citations

139

h-index

Top Research Topics

PI3K/AKT/mTOR signaling in cancer Protein Tyrosine Phosphatases Protein Kinase Regulation and GTPase Signaling

Top Researchers

Yang Liu Nanjing University of Chinese Medicine

3,016 works50,378 citationsh-index: 89

Recent Research

Prevalence of Obesity Medications in the Military Health System: An Update from 2022

Richele Corrado,Madison Meier,et al.

20260 citations

Ubiquitin and proteasome pathways

Melanoma and MAPK Pathways

Cancer Immunotherapy and Biomarkers

Peptidase Inhibition and Analysis

Signaling Pathways in Disease

Lung Cancer Treatments and Mutations

Historical Studies and Socio-cultural Analysis

Cancer, Hypoxia, and Metabolism

Cancer Genomics and Diagnostics

Wei Xing Division of Materials Science and Engineering

640 works36,482 citationsh-index: 87

Yang Liu University of Maryland, Baltimore

1,181 works34,192 citationsh-index: 98

Kevin Lin University of Hawaiʻi at Mānoa

832 works27,580 citationsh-index: 75

Daniel I. Simon University Hospitals of Cleveland

336 works23,280 citationsh-index: 73

Sam S. Chang University of California, Los Angeles

612 works19,606 citationsh-index: 64

Worker buyouts in Italy: capital structure patterns and financial vulnerabilities

Federico Pippo,Marco Pazzi,et al.

20260 citations

Cancer interception with KRAS inhibitors in preclinical models of pancreatic ductal adenocarcinoma

Minh T. Than,Lucie Dequiedt,et al.

20261 citations

Abstract B036: FYN antagonizes response to RAS inhibition in pancreatic ductal adenocarcinoma

Hsiu-Chi Ting,Sun Y. Kim,et al.

20260 citations

Abstract PR009: The RAS(ON) multi-selective inhibitor, daraxonrasib (RMC-6236), induces Receptor Tyrosine Kinase (RTK) cell surface expression on pancreatic cancer cells, providing rationale for combinations with RTK targeting agents

Yongxian Zhuang,Mark P. Labrecque,et al.

20260 citations

Abstract IA006: Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi- Selective Inhibitors in NRAS-Mutated Melanoma

Mona Foth,Wontak Kim,et al.

20260 citations